[Form 4] Royalty Pharma plc Insider Trading Activity
Terrance P. Coyne, EVP & CFO of Royalty Pharma plc (RPRX), reported an exempt acquisition on 08/06/2025 of 3,696 Class A Ordinary Shares in connection with the settlement of Equity Performance Awards. The filing shows the award settlement with a $0 price and cites the acquisition as exempt under Rule 16b-3.
The Form 4 shows the reporting person beneficially owned 52,342 Class A Ordinary Shares following the reported transaction, held indirectly through TPC RP EPA1 LLC. The filing also discloses additional indirect holdings including 790,000 shares held by TPC RP 2021, LLC, IRA and spouse accounts, and a reported disposal of 1,500 shares. The form was signed by attorney-in-fact on 08/08/2025.
Terrance P. Coyne, EVP e CFO di Royalty Pharma plc (RPRX), ha comunicato un'acquisizione esente in data 08/06/2025 di 3.696 azioni ordinarie di Classe A a seguito della liquidazione di Equity Performance Awards. La segnalazione indica che la liquidazione 猫 avvenuta a un prezzo di $0 e qualifica l'acquisizione come esente ai sensi della regola 16b-3.
Il Modulo 4 mostra che, dopo l'operazione riportata, la persona segnalante deteneva beneficiariamente 52.342 azioni ordinarie di Classe A, detenute indirettamente tramite TPC RP EPA1 LLC. La comunicazione evidenzia inoltre partecipazioni indirette aggiuntive, tra cui 790.000 azioni detenute da TPC RP 2021, LLC, conti IRA e del coniuge, oltre a una cessione riportata di 1.500 azioni. Il modulo 猫 stato firmato dal procuratore (attorney-in-fact) il 08/08/2025.
Terrance P. Coyne, EVP y CFO de Royalty Pharma plc (RPRX), notific贸 una adquisici贸n exenta con fecha 08/06/2025 de 3.696 acciones ordinarias Clase A en relaci贸n con la liquidaci贸n de Equity Performance Awards. El documento indica que la liquidaci贸n del premio se realiz贸 a un precio de $0 y califica la adquisici贸n como exenta en virtud de la Regla 16b-3.
El Formulario 4 muestra que la persona informante pose铆a beneficiariamente 52.342 acciones ordinarias Clase A tras la operaci贸n reportada, mantenidas de forma indirecta a trav茅s de TPC RP EPA1 LLC. La presentaci贸n tambi茅n revela tenencias indirectas adicionales, incluida la posesi贸n de 790.000 acciones por TPC RP 2021, LLC, cuentas IRA y del c贸nyuge, as铆 como una disposici贸n informada de 1.500 acciones. El formulario fue firmado por apoderado el 08/08/2025.
Terrance P. Coyne電� Royalty Pharma plc (RPRX)鞚� EVP 瓴� CFO搿滌劀 2025-08-06鞛愳棎 Equity Performance Awards 鞝曥偘瓿� 甏�霠暣 3,696欤� 韥措灅鞀� A 氤错喌欤�鞚� 鞓堨櫢鞝� 旆摑鞚� 鞁犼碃頄堨姷雼堧嫟. 鞝滌稖靹滊鞐愲姅 靾橂牴臧�臧� $0搿� 旮办灛霅橃柎 鞛堨溂氅�, 頃措嫻 旆摑鞚� Rule 16b-3 攴滌爼鞐� 霐半澕 鞓堨櫢搿� 攵勲霅橃柎 鞛堨姷雼堧嫟.
Form 4鞐愲姅 氤搓碃 雽�靸侅瀽臧� 氤搓碃霅� 瓯半灅 頉� 臧勳爲 氤挫湢 靾橂嫧鞚� TPC RP EPA1 LLC毳� 韱淀暣 52,342欤� 韥措灅鞀� A 氤错喌欤�毳� 鞁れ鞝侅溂搿� 氤挫湢頃橁碃 鞛堧姅 瓴冹溂搿� 響滌嫓霅橃柎 鞛堨姷雼堧嫟. 霕愴暅 鞝滌稖靹滊電� TPC RP 2021, LLC, IRA 氚� 氚办毎鞛� 瓿勳臧� 氤挫湢頃� 790,000欤� 霌膘潣 於旉皜 臧勳爲 氤挫湢鞕� 1,500欤�鞚� 觳橂秳 氤搓碃霃� 瓿奠嫓頃橁碃 鞛堨姷雼堧嫟. 頃措嫻 靹滊電� 雽�毽澑(Attorney-in-fact)鞐� 鞚橅暣 08/08/2025鞐� 靹滊獏霅橃棃鞀惦媹雼�.
Terrance P. Coyne, EVP et directeur financier de Royalty Pharma plc (RPRX), a d茅clar茅 une acquisition exon茅r茅e en date du 08/06/2025 de 3 696 actions ordinaires de cat茅gorie A dans le cadre du r猫glement d'Equity Performance Awards. Le d茅p么t indique que le r猫glement de la r茅compense s'est effectu茅 au prix de 0 $ et qualifie l'acquisition d'exon茅r茅e en vertu de la r猫gle 16b-3.
Le formulaire 4 montre que la personne d茅clarante d茅tenait b茅n茅ficiairement 52 342 actions ordinaires de cat茅gorie A apr猫s la transaction signal茅e, d茅tenues indirectement via TPC RP EPA1 LLC. Le d茅p么t r茅v猫le 茅galement des d茅tentions indirectes suppl茅mentaires, dont 790 000 actions d茅tenues par TPC RP 2021, LLC, des comptes IRA et du conjoint, ainsi qu'une cession signal茅e de 1 500 actions. Le formulaire a 茅t茅 sign茅 par un mandataire le 08/08/2025.
Terrance P. Coyne, EVP & CFO von Royalty Pharma plc (RPRX), meldete am 08/06/2025 einen als ausgenommen bezeichneten Erwerb von 3.696 Class A Stammaktien im Zusammenhang mit der Abwicklung von Equity Performance Awards. Die Meldung gibt an, dass die Awards zu einem Preis von $0 abgewickelt wurden und f眉hrt den Erwerb als von der Regel 16b-3 ausgenommen auf.
Aus Formular 4 geht hervor, dass die meldende Person nach der gemeldeten Transaktion wirtschaftlich 52.342 Class A Stammaktien hielt, die indirekt 眉ber TPC RP EPA1 LLC gehalten werden. Die Einreichung Offenlegt au脽erdem weitere indirekte Best盲nde, darunter 790.000 Aktien, die von TPC RP 2021, LLC, IRA- und Ehegattenkonten gehalten werden, sowie eine gemeldete Ver盲u脽erung von 1.500 Aktien. Das Formular wurde am 08/08/2025 vom Bevollm盲chtigten unterzeichnet.
- None.
- None.
Insights
TL;DR: Routine award settlement increases reported holdings modestly; disclosure appears compliant and likely carries limited immediate market impact.
The Form 4 documents an exempt acquisition of 3,696 Class A Ordinary Shares by EVP & CFO Terrance P. Coyne on 08/06/2025, settled as Equity Performance Awards with a reported price of $0. Post-transaction beneficial ownership is stated as 52,342 shares indirectly through TPC RP EPA1 LLC. The filing also lists larger indirect holdings (e.g., 790,000 via TPC RP 2021, LLC) and a small reported disposal of 1,500 shares. Overall this reads as a routine insider award settlement and disclosure; it does not, on its face, signal a material change to company fundamentals.
TL;DR: Disclosure shows complex indirect ownership and award settlement handled under Rule 16b-3; filing appears to meet Section 16 reporting requirements.
The filing includes explicit explanatory language that the acquisition was exempt under Rule 16b-3 and details conversion/exchange mechanics for RPI US LP interests into Class A Ordinary Shares under the Amended and Restated Exchange Agreement. The report enumerates multiple indirect ownership vehicles and related-party holdings (IRA, spouse), which are disclosed on the Form 4. From a governance and compliance perspective, the report provides the key required facts: transaction date, nature of acquisition, quantities, and beneficial ownership after the transaction.
Terrance P. Coyne, EVP e CFO di Royalty Pharma plc (RPRX), ha comunicato un'acquisizione esente in data 08/06/2025 di 3.696 azioni ordinarie di Classe A a seguito della liquidazione di Equity Performance Awards. La segnalazione indica che la liquidazione 猫 avvenuta a un prezzo di $0 e qualifica l'acquisizione come esente ai sensi della regola 16b-3.
Il Modulo 4 mostra che, dopo l'operazione riportata, la persona segnalante deteneva beneficiariamente 52.342 azioni ordinarie di Classe A, detenute indirettamente tramite TPC RP EPA1 LLC. La comunicazione evidenzia inoltre partecipazioni indirette aggiuntive, tra cui 790.000 azioni detenute da TPC RP 2021, LLC, conti IRA e del coniuge, oltre a una cessione riportata di 1.500 azioni. Il modulo 猫 stato firmato dal procuratore (attorney-in-fact) il 08/08/2025.
Terrance P. Coyne, EVP y CFO de Royalty Pharma plc (RPRX), notific贸 una adquisici贸n exenta con fecha 08/06/2025 de 3.696 acciones ordinarias Clase A en relaci贸n con la liquidaci贸n de Equity Performance Awards. El documento indica que la liquidaci贸n del premio se realiz贸 a un precio de $0 y califica la adquisici贸n como exenta en virtud de la Regla 16b-3.
El Formulario 4 muestra que la persona informante pose铆a beneficiariamente 52.342 acciones ordinarias Clase A tras la operaci贸n reportada, mantenidas de forma indirecta a trav茅s de TPC RP EPA1 LLC. La presentaci贸n tambi茅n revela tenencias indirectas adicionales, incluida la posesi贸n de 790.000 acciones por TPC RP 2021, LLC, cuentas IRA y del c贸nyuge, as铆 como una disposici贸n informada de 1.500 acciones. El formulario fue firmado por apoderado el 08/08/2025.
Terrance P. Coyne電� Royalty Pharma plc (RPRX)鞚� EVP 瓴� CFO搿滌劀 2025-08-06鞛愳棎 Equity Performance Awards 鞝曥偘瓿� 甏�霠暣 3,696欤� 韥措灅鞀� A 氤错喌欤�鞚� 鞓堨櫢鞝� 旆摑鞚� 鞁犼碃頄堨姷雼堧嫟. 鞝滌稖靹滊鞐愲姅 靾橂牴臧�臧� $0搿� 旮办灛霅橃柎 鞛堨溂氅�, 頃措嫻 旆摑鞚� Rule 16b-3 攴滌爼鞐� 霐半澕 鞓堨櫢搿� 攵勲霅橃柎 鞛堨姷雼堧嫟.
Form 4鞐愲姅 氤搓碃 雽�靸侅瀽臧� 氤搓碃霅� 瓯半灅 頉� 臧勳爲 氤挫湢 靾橂嫧鞚� TPC RP EPA1 LLC毳� 韱淀暣 52,342欤� 韥措灅鞀� A 氤错喌欤�毳� 鞁れ鞝侅溂搿� 氤挫湢頃橁碃 鞛堧姅 瓴冹溂搿� 響滌嫓霅橃柎 鞛堨姷雼堧嫟. 霕愴暅 鞝滌稖靹滊電� TPC RP 2021, LLC, IRA 氚� 氚办毎鞛� 瓿勳臧� 氤挫湢頃� 790,000欤� 霌膘潣 於旉皜 臧勳爲 氤挫湢鞕� 1,500欤�鞚� 觳橂秳 氤搓碃霃� 瓿奠嫓頃橁碃 鞛堨姷雼堧嫟. 頃措嫻 靹滊電� 雽�毽澑(Attorney-in-fact)鞐� 鞚橅暣 08/08/2025鞐� 靹滊獏霅橃棃鞀惦媹雼�.
Terrance P. Coyne, EVP et directeur financier de Royalty Pharma plc (RPRX), a d茅clar茅 une acquisition exon茅r茅e en date du 08/06/2025 de 3 696 actions ordinaires de cat茅gorie A dans le cadre du r猫glement d'Equity Performance Awards. Le d茅p么t indique que le r猫glement de la r茅compense s'est effectu茅 au prix de 0 $ et qualifie l'acquisition d'exon茅r茅e en vertu de la r猫gle 16b-3.
Le formulaire 4 montre que la personne d茅clarante d茅tenait b茅n茅ficiairement 52 342 actions ordinaires de cat茅gorie A apr猫s la transaction signal茅e, d茅tenues indirectement via TPC RP EPA1 LLC. Le d茅p么t r茅v猫le 茅galement des d茅tentions indirectes suppl茅mentaires, dont 790 000 actions d茅tenues par TPC RP 2021, LLC, des comptes IRA et du conjoint, ainsi qu'une cession signal茅e de 1 500 actions. Le formulaire a 茅t茅 sign茅 par un mandataire le 08/08/2025.
Terrance P. Coyne, EVP & CFO von Royalty Pharma plc (RPRX), meldete am 08/06/2025 einen als ausgenommen bezeichneten Erwerb von 3.696 Class A Stammaktien im Zusammenhang mit der Abwicklung von Equity Performance Awards. Die Meldung gibt an, dass die Awards zu einem Preis von $0 abgewickelt wurden und f眉hrt den Erwerb als von der Regel 16b-3 ausgenommen auf.
Aus Formular 4 geht hervor, dass die meldende Person nach der gemeldeten Transaktion wirtschaftlich 52.342 Class A Stammaktien hielt, die indirekt 眉ber TPC RP EPA1 LLC gehalten werden. Die Einreichung Offenlegt au脽erdem weitere indirekte Best盲nde, darunter 790.000 Aktien, die von TPC RP 2021, LLC, IRA- und Ehegattenkonten gehalten werden, sowie eine gemeldete Ver盲u脽erung von 1.500 Aktien. Das Formular wurde am 08/08/2025 vom Bevollm盲chtigten unterzeichnet.
